The pursuit of susceptibility genes for Alzheimer's disease: progress and 
prospects.

Sleegers, K.; Lambert, J. C.; Bertram, L.; Cruts, M.; Amouyel, P.; Van Broeckhoven, C.

doi:10.1016/j.tig.2009.12.004

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects.

MPS-Authors

/persons/resource/persons50098

Bertram, L.
Neuropsychiatric Genetics (Lars Bertram), Dept. of Vertebrate Genomics (Head: Hans Lehrach), Max Planck Institute for Molecular Genetics, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Sleegers, K., Lambert, J. C., Bertram, L., Cruts, M., Amouyel, P., & Van Broeckhoven, C. (2010). The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects. Trends in Genetics, 26(2), 84-93. doi:10.1016/j.tig.2009.12.004.

Cite as: https://hdl.handle.net/11858/00-001M-0000-0010-7C12-8

Abstract

The recent discoveries in genome-wide association studies (GWAS) of novel susceptibility loci (CLU, CR1 and PICALM) for Alzheimer's disease (AD) have elicited considerable interest in the AD community. But what are the implications of these purely epidemiological findings for our understanding of disease etiology and patient care? In this review, we attempt to place these findings in the context of current and future AD genetics research. CLU, CR1 and PICALM support existing hypotheses about the amyloid, lipid, chaperone and chronic inflammatory pathways in AD pathogenesis. We discuss how these and future findings can be translated into efforts to ameliorate patient care by genetic profiling for risk prediction and pharmacogenetics and by guiding drug development.